One other tidbit this week: turns out we’d been given incorrect information about the Apomab drug trial ditching the placebo. This week (with some chagrin) oncology staff let us know Val’s Apomab trail is unchanged, and half the participants will still receive a placebo instead of the drug, although that can vary from infusion to infusion. (So you might get the drug, say, for two rounds, and then get the placebo the next time.) Anyway, the new info is this:
Apomab is being used in trials to treat some other kinds of cancer too, and they (the company? the government?) approved its use without placebo in a trial similar to Val’s. This is still hopeful news, according to our research nurse, who says that means it’s more likely that they will also ditch the placebo in Val’s trial sooner or later and give all participants the actual drug.
Stay tuned…
Deborah
One thought on “Apomab redux”
Comments are closed.